Acuta Capital Partners LLC Takes Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Acuta Capital Partners LLC purchased a new position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,979,199 shares of the company’s stock, valued at approximately $807,000. Unicycive Therapeutics makes up 0.7% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 27th largest holding.

Several other institutional investors also recently bought and sold shares of UNCY. Great Point Partners LLC purchased a new position in Unicycive Therapeutics in the third quarter worth about $3,491,000. Bleakley Financial Group LLC bought a new stake in shares of Unicycive Therapeutics during the third quarter valued at approximately $33,000. Finally, Virtu Financial LLC purchased a new position in Unicycive Therapeutics in the 1st quarter worth approximately $36,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UNCY has been the topic of several recent analyst reports. Benchmark reiterated a “speculative buy” rating and set a $3.00 target price on shares of Unicycive Therapeutics in a research note on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price objective on shares of Unicycive Therapeutics in a research report on Tuesday, November 12th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $5.13.

Unicycive Therapeutics Trading Up 14.9 %

NASDAQ:UNCY opened at $0.68 on Thursday. The company has a 50 day simple moving average of $0.45 and a two-hundred day simple moving average of $0.51. The company has a market cap of $70.37 million, a PE ratio of -0.61 and a beta of 2.29. Unicycive Therapeutics, Inc. has a 12 month low of $0.20 and a 12 month high of $1.82.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.